In order to ensure transparency on the surveillance of authorised medicinal products, the list of medicinal products subject to additional monitoring established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [OJ L 136, 30.4.2004, p. 1.], should systematically include medicinal products that are subject to certain post-authorisation safety conditions.
Recital 1, Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October…
In force